Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Brotchie

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Experimental Neurology|June 12, 2004
Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primateM A Silverdale, S L Nicholson, P Ravenscroft, et al.
Neurology|December 12, 2001
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot studyK A Sieradzan, S H Fox, M Hill, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 16, 1998
Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonismN R Hughes, A T McKnight, G N Woodruff, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 23, 2020
NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease ModelA L Barth, J S Schneider, T H Johnston, et al.
Neuropharmacology|March 10, 2005
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's diseaseP J Hallett, A W Dunah, P Ravenscroft, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 23, 2001
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's diseaseE Bezard, S Dovero, C Prunier, et al.
Experimental Neurology|August 31, 2000
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's diseaseJ E Nash, S H Fox, B Henry, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Experimental Neurology|June 12, 2004
Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primateM A Silverdale, S L Nicholson, P Ravenscroft, et al.
Neurology|December 12, 2001
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot studyK A Sieradzan, S H Fox, M Hill, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 16, 1998
Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonismN R Hughes, A T McKnight, G N Woodruff, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 23, 2020
NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease ModelA L Barth, J S Schneider, T H Johnston, et al.
Neuropharmacology|March 10, 2005
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's diseaseP J Hallett, A W Dunah, P Ravenscroft, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 23, 2001
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's diseaseE Bezard, S Dovero, C Prunier, et al.
Experimental Neurology|August 31, 2000
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's diseaseJ E Nash, S H Fox, B Henry, et al.
Pageof 6